Oncolytic Virus-Based Therapies for Neurological Disorders
Legal Citation
Summary of the Inventive Concept
The present invention expands the application of oncolytic viruses to neurological disorders, offering novel therapeutic approaches for treating conditions such as glioblastoma, Parkinson's disease, and spinal cord injuries.
Background and Problem Solved
While oncolytic viruses have shown promise in cancer treatment, their potential in addressing neurological disorders remains largely unexplored. The original patent's oncolytic virus, with its improved safety and anticancer effect, provides a foundation for exploring new applications in the field of neurology. However, the original patent's limitations in terms of targeted delivery and combination therapies for neurological disorders necessitate the development of new approaches.
Detailed Description of the Inventive Concept
The inventive concept involves the use of the recombinant oncolytic virus of claim 1 in treating neurological disorders. This includes methods for direct administration of the virus to the central nervous system, systems for targeted delivery to specific regions of the brain or spinal cord, and pharmaceutical compositions combining the virus with neural stem cells or stem cell therapies. The oncolytic virus's ability to selectively target and destroy cancer cells is leveraged to address the complex pathologies of neurological disorders.
Novelty and Inventive Step
The new claims introduce novel applications of the oncolytic virus in neurological disorders, which were not anticipated by the original patent. The inventive step lies in the recognition of the virus's potential in treating conditions beyond cancer and the development of targeted delivery systems and combination therapies to address the unique challenges of neurological disorders.
Alternative Embodiments and Variations
Alternative embodiments may include the use of different viral vectors, varying dosing regimens, or combination therapies with other neurologically active compounds. Variations may also involve adapting the delivery systems for use in different animal models or human clinical trials.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the neurology market, with potential applications in treating glioblastoma, Parkinson's disease, spinal cord injuries, and other neurological disorders. The market for neurological disorder treatments is substantial, with an estimated global value of over $100 billion.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K35/768 |
| A | A61 | A61K9/0019 |
| A | A61 | A61K31/708 |
| C | C12 | C12N15/86 |
| C | C12 | C12N2710/24111 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Virology, gene therapy, and neurological disorder treatment, with expertise in recombinant viral technologies, targeted drug delivery, and therapeutic applications of oncolytic viruses
Person of Ordinary Skill (PHOSITA) Profile
A researcher or medical professional with advanced degrees in molecular biology, virology, or neuroscience, possessing knowledge of viral vector design, gene modification techniques, and therapeutic applications of engineered viruses
Obviousness Rationale
A PHOSITA would recognize the natural extension of the oncolytic virus technology from cancer treatment to neurological disorders based on the virus's inherent targeting capabilities and the known challenges in treating complex neurological conditions. The systematic approach of adapting the viral vector for new therapeutic applications represents a predictable variation within the existing technological framework. The PTD demonstrates a logical progression of applying the virus's selective targeting mechanism to alternative medical contexts.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,585 |
|---|---|
| Title | Oncolytic virus improved in safety and anticancer effect |
| Assignee(s) | BIONOXX INC. |